IPA: Inhibition of platelet aggregation; iv.: Intravenous. 1 Department of Cardiology, University of Ioannina, 45110 Ioannina, Greece 2 Laboratory of Biochemistry, Department of Chemistry ...
SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia ...
Factor VIII gene was introduced into hematopoietic stem cells in men with hemophilia. The annualized bleeding rate went from 10 to 0. No worrisome gene integrations were seen. The content of this ...
Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which ...
In the laboratory, they will undoubtedly stimulate renewed interest in how autoantibodies inhibit megakaryocyte maturation and platelet production. Inconsistent effects of autoantibodies have been ...
inhibitor, and further support its potential as a first-in-class treatment for ITP. Platelet response was achieved in 65% (n=86) of patients receiving rilzabrutinib compared to 33% (n=23 ...
IPA: Inhibition of platelet aggregation; iv.: Intravenous. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback